HALO

Halozyme Therapeutics, Inc. is a biotechnology company that develops and commercializes novel oncology therapies and drug delivery technologies. Headquartered in San Diego, California, the company operates primarily through its proprietary ENHANZE® drug delivery technology, which uses recombinant human hyaluronidase enzyme (rHuPH20) to increase the dispersion and absorption of injected biologics. Halozyme generates revenue through both proprietary product sales and royalty payments from licensed partners who incorporate ENHANZE® into their therapeutic products. The company's proprietary oncology portfolio includes XYOMIC® (bevacizumab-njns) for colorectal and lung cancers, and PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf), developed with Roche for HER2-positive breast cancer. As of 2024, Halozyme has licensed its ENHANZE® technology to major pharmaceutical companies including Roche, Takeda, Pfizer, AbbVie, and Johnson & Johnson, with multiple FDA-approved products utilizing the platform. The company employs approximately 400 people and maintains manufacturing facilities in California. Recent strategic developments include expanding its royalty-generating partnerships, advancing its wholly-owned oncology pipeline, and implementing share repurchase programs. Halozyme transitioned from a primarily partnered revenue model to one incorporating proprietary product sales, positioning itself as both a platform technology licensor and emerging specialty pharmaceutical company in the oncology space.